Sunday, October 9, 2011

Competition for Early-Line Biologic Use among Psoriasis Patients Intensifies ... - EON: Enhanced Online News (press release)

Competition for Early-Line Biologic Use among disease of the skin Patients Intensifies ... EON: Enhanced Online News (press release) According to brand-new analysis of US patient-level claims data, while Enbrel remains the most usually used biologic in the treatment of psoriasis , Humira continues to see sustained quarter-over-quarter uptake among recently treated psoriasis patients, ... and more » Link To Article

No comments:

Post a Comment